Featured Press Releases

Doer Biologics announces the dosing of the first patient in a Phase 2 study of DR10624 for severe hypertriglyceridemia treatment.

Doer Biologics announces the dosing of the first patient in a Phase 2 study of DR10624 for severe hypertriglyceridemia treatment.

Grindeks_17022025

"Grindeks, the leading pharmaceutical company in the Baltics, expands to new export markets worldwide

  • 17 Feb 2025

The leading pharmaceutical company in the Baltics, Grindeks, continues to strengthen its global...

Transposon to share Phase 2 results of TPN-101 for C9orf72-related ALS/FTD at ALS ONE Research Symposium.

Transposon to share Phase 2 results of TPN-101 for C9orf72-related ALS/FTD at ALS ONE Research Symposium.

Zydus announces an exclusive licensing and supply agreement for two Gadolinium-based MRI injectable contrast agents in the U.S

Zydus announces an exclusive licensing and supply agreement for two Gadolinium-based MRI injectable contrast agents in the U.S

Kenox Pharmaceuticals announces a strategic collaboration with Lactiga to advance immunotherapy targeting mucosal areas

Kenox Pharmaceuticals announces a strategic collaboration with Lactiga to advance immunotherapy targeting mucosal areas

NLS Pharmaceutics and Kadimastem announce a $500,000 initial closing of a $1 million fundraising, with shares priced at $3.10, a 48% premium over the January 6, 2025 market price

NLS Pharmaceutics and Kadimastem announce a $500,000 initial closing of a $1 million fundraising, with shares priced at $3.10, a 48% premium over the January 6, 2025 market price

Niagen Bioscience

Niagen Bioscience's Pharmaceutical-Grade Niagen™ IV and Injections Are Now Available at Over 50 iCRYO Clinics and More Than 900 Clinics Nationwide

  • Niagen Bioscience, Inc
  • 01 Oct 2025
Novartis Receives FDA Approval for Rhapsido® (remibrutinib), the First Oral, Targeted BTKi Treatment for Chronic Spontaneous Urticaria (CSU

Novartis Receives FDA Approval for Rhapsido® (remibrutinib), the First Oral, Targeted BTKi Treatment for Chronic Spontaneous Urticaria (CSU

  • Novartis Pharmaceuticals Corporation
  • 01 Oct 2025
CollPlant Biotechnologies Announces Positive Non-Clinical Study Results for Its Photocurable Regenerative Dermal and Soft Tissue Filler

CollPlant Biotechnologies Announces Positive Non-Clinical Study Results for Its Photocurable Regenerative Dermal and Soft Tissue Filler

  • CollPlant
  • 30 Sep 2025
Corstasis Therapeutics and U.S. Heart and Vascular® will collaborate to improve heart failure care with ENBUMYST™ (Bumetanide Nasal Spray

Corstasis Therapeutics and U.S. Heart and Vascular® will collaborate to improve heart failure care with ENBUMYST™ (Bumetanide Nasal Spray

  • Corstasis Therapeutics Inc.
  • 29 Sep 2025
Leqembi® has received approval for intravenous maintenance treatment in China

Leqembi® has received approval for intravenous maintenance treatment in China

  • BioArctic AB
  • 29 Sep 2025
At the Heart Failure Society of America, Bayer will showcase new data for KERENDIA® (finerenone)

At the Heart Failure Society of America, Bayer will showcase new data for KERENDIA® (finerenone)

  • Bayer
  • 25 Sep 2025

Most Popular
October   2025
M T W T F S S
    1 2 3 4 5
6 7 8 9 10 11 12
13 14 15 16 17 18 19
20 21 22 23 24 25 26
27 28 29 30 31    

User Area

Discover

Engage with Us

© 2024 Pharmaceutical Era — A product of HISSM. All Rights Reserved.